认为对转移性癌症至关重要的四氯化碳测试,将在五年内成为常规,得到全球专家和90%的支持。 CTC testing, seen as vital for metastatic cancer, is poised to become routine in five years, backed by global experts and 90% support.

《欧洲癌症期刊》发表的主要国际专家共识肯定了循环肿瘤细胞(CTCs)在癌症护理方面的临床价值,指出这些细胞提供了无法通过CtDNA获得的独特洞察力,并预测CTC检测将在五年内成为临床实践的常规,特别是对转移性癌症而言。 A major international expert consensus published in the European Journal of Cancer affirms the clinical value of circulating tumor cells (CTCs) in cancer care, stating they provide unique insights not available through ctDNA and predicting CTC testing will become routine in clinical practice within five years, especially for metastatic cancer. 这一共识由32个全球肿瘤学家形成,发现90%支持将四氯化碳纳入肿瘤学,40%认为细胞健康(Cellbxhealth)Parsortix平台是最有希望的技术。 The consensus, developed by 32 global oncologists, found 90% support for CTC integration into oncology, with 40% identifying Cellbxhealth’s Parsortix® platform as the most promising technology. 该公司报告在2026年初开通了一条现金跑道,正试图通过零售和提供机构来筹集600万英镑,预计12月初会宣布。 The company, which reported a cash runway into early 2026, is seeking to raise £6 million through a retail and institutional offering, with an announcement expected by early December. 该同行审评研究可在网上查阅。 The peer-reviewed study is available online.